NCT04028479: The Master Registry of Oncology Outcomes Associated With Testing and Treatment

NCT04028479
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine Tumor (NET)
Recruitment Status: Not yet recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who are not candidates for systemic therapy
https://ClinicalTrials.gov/show/NCT04028479

Comments are closed.

Up ↑